M. Picone

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Screening Instruments for the Early Detection of Cognitive Impairment in Patients with Multiple Sclerosis.

F. Foley, E. Gromisch, V. Zemon, 2017, International journal of MS care.

Individual reserve in aging and neurological disease

R. Motl, R. Holtzer, M. Hernandez, 2023, Journal of Neurology.

Illness intrusiveness: A key part of the cognition-mood link in multiple sclerosis.

F. Foley, C. Swencionis, E. Seng, 2022, Rehabilitation psychology.

Differential Associations of Mobility With Fronto-Striatal Integrity and Lesion Load in Older Adults With and Without Multiple Sclerosis

R. Motl, R. Holtzer, M. Hernandez, 2023, Neurorehabilitation and neural repair.

Predictors of changes in suicidality in multiple sclerosis over time

Helen R. Quinn, F. Foley, V. Zemon, 2014, Disability and rehabilitation.